CMP-002

CAMP4 Therapeutics Receives EU Approval to Advance CMP-002 Phase 1/2 Trial for SYNGAP1-Related Disorder

WATERTOWN, Massachusetts, United States — October 27, 2026 CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics,...

By cGxPwire Editor
October 29, 2026

Bio-Pharma

CAMP4 Therapeutics Prepares CMP-002 Phase 1/2 Trial for SYNGAP1

WATERTOWN, Mass. — September 8, 2026 CAMP4 Therapeutics Corporation announced plans to host a virtual Analyst Day on September...

By cGxPwire Editor
September 10, 2026

Bio-Pharma

CAMP4 Therapeutics Receives Australian Clearance for First-in-Human CMP-002 Trial

CAMBRIDGE, Mass., July 27, 2026 CAMP4 Therapeutics announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration...